Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK: results from two matched case–control studies

Maha Abo-Tabik, Rosa Parisi, Catharine Morgan, Sarah Willis, Christopher EM Griffiths and Darren M Ashcroft on behalf of the Global Psoriasis Atlas

INTRODUCTION
Psoriasis is a systemic, inflammatory, long-term disease with characteristic clinical signs. It affects the quality of life of affected individuals to a substantial degree; however, its overall effect often extends beyond the skin, being associated with other medical conditions such as psoriatic arthritis, cardiovascular disease, respiratory diseases, liver disease, and depression. Disease progression in psoriasis is unpredictable in that some patients have mild disease that is stable for many years, whereas, for others, it quickly progresses to moderate-to-severe disease. Thus, psoriasis is a complex health problem that requires a comprehensive care approach for both early diagnosis and treatment. The global prevalence of psoriasis is estimated to be 0.59% in adults and about 0.47% in the overall population, and psoriasis affects around 3% of the general population in the UK. Epidemiological studies suggested that the burden of psoriasis is greater in high-income countries of North America and Europe than in other regions. In 2014, the World Health Organization (WHO) highlighted that many people in the world suffer needlessly from psoriasis because of an incorrect or delayed diagnosis. The WHO also emphasised the psychological and pathological consequences of a delayed or incorrect diagnosis of psoriasis and recognised this as a global concern.

Present treatment approaches are aimed at providing individualised care that focuses on improving the signs and symptoms of the rash while proactively screening for and treating any associated comorbidities. More recently, increasing efforts are being made to trial the impact of early intervention targeting complete clearance, which may improve control of psoriasis and may also modify disease course and burden. To address this, psoriasis needs to be recognised early.

The impact of the delay in the diagnosis and treatment of psoriatic arthritis has previously been investigated and it has...
been suggested that a ≥6-month delay in this diagnosis and initiation of treatment is associated with deterioration in patients’ quality of life in comparison with shorter periods. In the case of psoriasis, a multicentre international observational study reported on the diagnostic delay and estimated this to be 1.6 years (standard deviation 4.8) on average. The diagnosis of psoriasis relies on the identification of clinical features, which are incorporated into clinical diagnostic criteria. However, its variable clinical presentation and resemblance to other skin conditions (for example, eczema and tinea corporis) make it difficult to recognise, especially in those populations where access to specialist dermatology care is restricted, which may result in missed or delayed diagnosis.

In many countries, including the UK, primary care professionals represent the first point of contact for people with dermatological conditions including psoriasis. Despite being one of the most commonly seen skin conditions in a primary care setting, there is a lack of studies on missed or delayed diagnosis of psoriasis. The primary aim of this study was to examine the electronic health records (EHRs) of individuals with and without psoriasis and to investigate incident rates of other differential diagnoses, characteristic clinical features, and treatments.

**METHOD**

**Data source, participants, and study design**

Data from the Clinical Practice Research Datalink (CPRD) were used in the study. The CPRD is one of the largest databases of longitudinal health records from primary care in the world. Data from CPRD are divided into two databases depending on the information technology system the general practice uses for their patient management. General practices using Vision software contribute to CPRD Gold and those using EMIS Web software contribute to CPRD Aurum. CPRD GOLD has contributing general practices from across the UK whereas CPRD Aurum collects anonymised health records from general practices predominately in England. The population coverage of the dataset is considered to be representative in terms of age, sex, ethnicity, and geographical distributions of the UK general population.

The study is reported in line with the recommendations of the RECORD statement. This case-control study was conducted using de-identified EHRs that were extracted by a third party and anonymised before being made available for research purposes. Thus, no patient consent was required.

Participants were included as ‘incident cases’ of psoriasis diagnosed between 1 January 2010 and 29 December 2017. Each individual with psoriasis was matched with six eligible individuals without a diagnosis of psoriasis. The matching was undertaken on calendar time (index date of cases), the exact year of birth, sex, and registered general practice.

**Clinical events of interest**

An a priori list of clinical events that could potentially be related to missed opportunities for psoriasis diagnosis in primary care settings was identified.

Clinical events of interest were grouped into three categories:

- differential diagnosis for psoriasis;
- clinical features; and
- prescribed medications (Supplementary Table S1).

Diagnoses and clinical features were identified by Read codes. The list of clinical events was reviewed by one of the authors, who is an experienced dermatologist, to ensure clinical relevance to the aims and objectives of the study.

**Differential diagnosis.** Potential differential diagnoses of psoriasis included seborrheic dermatitis, other eczema (including contact dermatitis, atopic dermatitis, neurodermatitis, discoid eczema,
Asteatotic eczema, and hand dermatitis), tinea corporis, candidal dermatoses, and pityriasis rosea.

Clinical features. The number of times that people in the case group and control group consulted their GP with clinical features that were considered suggestive of psoriasis was examined. Clinical features that may precede a diagnosis of psoriasis included itching, dry skin, rash, and changes in skin texture (scale, plaque, and crust).

Prescribed medications. Two groups of medications that are often prescribed for people before their diagnoses of psoriasis is confirmed were identified. These included topical corticosteroids and topical antifungals from the British National Formulary [BNF].

Data analysis
Descriptive statistics were used to calculate the median and interquartile range (IQR) for demographic characteristics. Age at index date, sex, geographical region at the general practice level, and socioeconomic status based on the Index of Multiple Deprivation (IMD) were used as a measure of socioeconomic deprivation of residential neighbourhood, which was linked at the general practice level. The frequency of GP visits was also considered. Absolute numbers (that is, total numbers in the case and control groups) and their frequency (or proportion) were used to report on demographic data analysis.

Incidence rates and 95% confidence intervals [CIs] were calculated for each clinical event (differential diagnosis, clinical features, and prescribed medication) per 1000 person-years for each year within 10 years before the index date for individuals with and without psoriasis. The incidence rate ratios (IRRs) and 95% CIs were also calculated for each clinical event at 6 months, 1 year, 3 years, and 5 years before index date for the case and control groups.

RESULTS
CPRD GOLD dataset
Demographic characteristics. The study population was extracted from 796 participating GP practices. In total, 17 320 individuals with incident diagnosis of psoriasis were identified from CPRD GOLD and matched to 99 320 individuals without a psoriasis diagnosis. The baseline demographic characteristics are described in Table 1. Median age at index date was 51 (IQR 36–64) and 50 (IQR 36–64) years for the case and control groups, respectively; sex was 52.18% female and 47.82% male in both groups.

Frequency of GP consultations. Overall, individuals with psoriasis were more likely to visit their GP than those without psoriasis (Table 1). Visits to the GP practices for individuals with psoriasis increased during the 5-year period before the index date by almost 60%, from a median of 7 (IQR 2–13) per year at 5 years before the index date to 11 (IQR 5–19) visits per year at 1 year before the index date. In comparison, the frequency of GP consultations for those without psoriasis showed a less noticeable increase from 5 (IQR 2–12) to 8 (IQR 4–15) over the same 5-year period before the index date.

Differential diagnosis. People in the case group were more likely to receive a diagnosis of pityriasis rosea, eczema, seborrheic dermatitis, tinea corporis, and candidal dermatoses than those in the comparator group from 5 years before the index date. The incidence rates of being diagnosed with one of the aforementioned skin conditions were markedly higher for the case group than those without psoriasis.

Table 1. Baseline demographic characteristics of the study population (CPRD GOLD)

| Total | Case group (n = 17 320) | Control group (n = 99 320) |
|-------|------------------------|---------------------------|
| Sex, n(%) | Male 8282 (47.82) | 47 491 (47.82) |
|        | Female 9038 (52.18) | 51 829 (52.18) |
| Age at index, years, median (IQR) | 51 (36–64) | 50 (36–64) |
| Region, n(%) | London 2457 (14.19) | 14 023 (14.12) |
|        | South England 7227 (41.73) | 41 626 (41.91) |
|        | Midlands and East England 3831 (22.12) | 21 924 (22.07) |
|        | North England 3805 (21.97) | 21 747 (21.90) |
| Number of GP consultations before the index date, median (IQR) | | |
| 4–5 years before index date | 7 (2–13) | 5 (2–12) |
| 3–4 years before index date | 8 (3–15) | 6 (2–12) |
| 2–3 years before index date | 8 (3–16) | 6 (2–13) |
| 1–2 years before index date | 10 (5–18) | 8 (4–15) |
| 0–1 year before index date | 11 (5–19) | 8 (4–15) |
| Socioeconomic status, IMD quintile, n(%) | | |
| 1 (least deprived) | 4020 (23.21) | 23 997 (24.16) |
| 2 | 3830 (22.11) | 22 405 (22.56) |
| 3 | 3422 (19.76) | 19 553 (19.69) |
| 4 | 3343 (19.30) | 18 775 (18.90) |
| 5 (most deprived) | 2695 (15.56) | 14 533 (14.63) |

CPRD = Clinical Practice Research Datalink. IMD = Index of Multiple Deprivation. IQR = interquartile range. Missing data: cases 10 (0.06%) and controls 57 (0.06%).
Table 2. IRRs of clinical events recorded 6 months, 1, 3, and 5 years before the index date (CPRD GOLD)

| Clinical events                | 6 months, IRR (95% CI) | 1 year, IRR (95% CI) | 3 years, IRR (95% CI) | 5 years, IRR (95% CI) |
|--------------------------------|------------------------|----------------------|-----------------------|-----------------------|
| Seborrheic dermatitis          | 2.34 (1.82 to 3.00)    | 1.97 (1.65 to 2.35)  | 1.49 (1.33 to 1.66)   | 1.27 (1.13 to 1.38)   |
| Eczema                         | 2.23 (1.99 to 2.50)    | 1.90 (1.76 to 2.05)  | 1.41 (1.35 to 1.48)   | 1.23 (1.18 to 1.28)   |
| Tinea corporis                 | 2.52 (2.09 to 3.03)    | 1.99 (1.74 to 2.27)  | 1.43 (1.32 to 1.56)   | 1.25 (1.17 to 1.34)   |
| Candida skin infections        | 1.46 (1.32 to 1.74)    | 1.44 (1.29 to 1.61)  | 1.28 (1.20 to 1.37)   | 1.15 (1.08 to 1.21)   |
| Pityriasis rosea               | 7.82 (4.09 to 14.95)   | 3.24 (2.24 to 5.27)  | 1.71 (1.28 to 2.27)   | 1.38 (1.09 to 1.75)   |
| Dry skin                       | 2.05 (1.54 to 2.72)    | 1.52 (1.24 to 1.86)  | 1.38 (1.22 to 1.57)   | 1.08 (1.06 to 1.30)   |
| Rash                           | 4.00 (3.62 to 4.41)    | 2.71 (2.53 to 2.92)  | 1.63 (1.55 to 1.71)   | 1.32 (1.27 to 1.38)   |
| Skin texture changes           | 2.17 (1.69 to 2.29)    | 1.55 (1.39 to 1.77)  | 1.23 (1.14 to 1.31)   | 1.13 (1.06 to 1.20)   |
| Itching                        | 1.39 (1.00 to 1.93)    | 1.54 (1.22 to 1.94)  | 1.26 (1.10 to 1.45)   | 1.18 (1.05 to 1.32)   |
| Topical corticosteroids        | 2.58 (2.39 to 2.79)    | 1.97 (1.88 to 2.07)  | 1.46 (1.42 to 1.50)   | 1.24 (1.21 to 1.27)   |
| Topical antifungal treatment   | 2.32 (2.08 to 2.59)    | 1.92 (1.78 to 2.07)  | 1.43 (1.36 to 1.49)   | 1.24 (1.20 to 1.29)   |

CPRD = Clinical Practice Research Datalink. IRR = incidence rate ratio.

Funding
The University of Manchester covered the funding for this study. The Global Psoriasis Atlas has been supported by: The LEO Foundation, Abbvie, Almirall, Amgen, Janssen, Eli Lilly and Company, Novartis Pharma AG, and UCB (2021/22). Darren M Ashcroft is funded by the National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (award number: PSTRC-2016–003). Christopher EM Griffiths is funded in part by the NIHR Manchester Biomedical Research Centre. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed are those of the authors alone and not necessarily those of the NIHR or the Department of Health and Social Care.

Ethical approval
The study was approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare products Regulatory Agency database research (ISAC approval: 18_308R) in the UK. in the final year before the index date, as shown in Table 2.

Individuals with psoriasis were almost eight times more likely to be diagnosed with pityriasis rosea (Figure 1a) and twice as likely to be diagnosed with seborrheic dermatitis (Figure 1b) and eczema (Figure 1d) within the year before the index date than those in the control group.

In addition, individuals with psoriasis were 2.5 times more likely to be diagnosed with tinea corporis (Figure 1c) and 1.5 times more likely to be diagnosed with candidal dermatoses (Figure 1e) in the final year before the index date than those without psoriasis.

Clinical features. People with psoriasis more frequently reported rash, dry skin, and skin texture changes (including scales, plaque, and crust) than those without a psoriasis diagnosis before the index date, as shown in Table 2.

The most frequently reported clinical feature was skin rash (Figure 2a). Those who ended up with a psoriasis diagnosis were four times more likely to report skin rash in the final year before the index date than those in the control group.

People in the case group were twice as likely to report dry skin (Figure 2b) and skin texture changes (Figure 2c) in the final year before the index date than those in the control group.

Individuals in the control group were only slightly more likely to report itching than those in the control group (Figure 2d).

Prescribed medications. There was an increasing likelihood of a person in the case group being prescribed topical corticosteroids or topical antifungal medication closer to the index date compared with the control group, as shown in Table 2.

Those with a confirmed psoriasis diagnosis were almost twice as likely to be prescribed topical corticosteroids (Figure 3a) or topical antifungals (Figure 3b) within the final year before the index date (that is, date of documented psoriasis diagnosis) than those in the control group. Closer to the index date (at 6 months before a confirmed psoriasis diagnosis), people in the case group were 2.5 and 2.3 times more likely to receive topical corticosteroids and topical antifungal medication, respectively, than those in the control group.

The IRR for all investigated clinical events at 6 months, 1 year, 3 years, and 5 years before the index date is shown in Table 2.

CPRD Aurum dataset
Data from CPRD Aurum showed similar findings to CPRD GOLD. In total, 11 442 people with an incident psoriasis diagnosis and 65 840 without psoriasis were included in this study. The baseline demographic characteristics of the study cohort are shown in Supplementary Table S2. The median age was 50 (IQR 35–64) years for both the case and control groups. The female:male ratio was similar for the case and control groups with almost 52% female and 48% male patients (cases = male 8282, female 9038; controls = male 47 491, female 51 829). The study population was extracted from 176 GP practices contributing to the CPRD Aurum database.

The frequency of GP consultations increased steadily from seven visits in...
5 years before the index date to 12 visits in the final year before the index date, as shown in Supplementary Table S2.

Trends for incidence rates for the examined clinical events (differential diagnosis, clinical features, and prescribed medication) were all similar to the findings from CPRD GOLD. The annual incidence rate for the investigated possible missed clinical events are shown in Supplementary Figures S1–S3. The IRRs are shown in Supplementary Table S3.

**DISCUSSION**

**Summary**

To the authors’ knowledge, this is the first study to retrospectively analyse data collected from medical records to investigate primary care consultations before a diagnosis of psoriasis. This has resulted in the identification of premonitory
clinical events that could potentially be related to a diagnosis of psoriasis before it is made. The current study found that people with psoriasis were more likely to visit general practices than those without psoriasis from 5 years before the index date.

Patients in the case group had higher chances of being diagnosed with skin conditions other than psoriasis before the index date (that is, date of confirmed psoriasis diagnosis) than those in the control group. Such skin conditions included pityriasis rosea, eczema, and/or fungal infections. Additionally, the study found higher reporting of symptoms related to psoriasis such as rash, dry skin, and skin texture changes in individuals who eventually developed psoriasis than in those without psoriasis.

Individuals with psoriasis were more likely to be prescribed a topical corticosteroid or antifungal medication before a documented diagnosis of psoriasis than were patients in the control group. The frequent use of these medications could mask signs and symptoms of psoriasis and contribute to further delay in diagnosis.

All the examined healthcare events (that is, differential diagnosis, clinical features, and prescribed medications) tend to increase through the 5 years before the index date among people with psoriasis. Hence, this suggests possible delays in psoriasis diagnosis of up to 5 years for some individuals.

**Strengths and limitations**

The main strength of the study is that two independent case–control studies were conducted using primary care EHRs [CPRD GOLD and CPRD Aurum] and similar findings are reported in the two studies. Additionally, data recorded in the EHR are recorded prospectively thereby minimising the risk of recall bias.

The main limitation of this study is that only individuals aged ≥18 years were included, thus missed opportunities for psoriasis diagnosis among younger individuals at risk were not explored.

The other limitation is the lack of comparison across skin of colour. Psoriasis

**Figure 2. Annual incidence rate per 1000 person–years of recording clinical features suggestive of psoriasis from 10 years before the index date. a) Rash; b) dry skin; c) skin texture changes; and d) itching. Bars are 95% confidence intervals (CPRD GOLD). CPRD = Clinical Practice Research Datalink.**

**Data**

This study used anonymised patient-level data from the Clinical Practice Research Datalink (CPRD) that are not publicly available because of confidentiality considerations. However, researchers can access CPRD’s databases by contacting the Medicines and Healthcare products Regulatory Agency. Details of the application process and conditions of access are available at https://www.cprd.com/Data-access.

**Provenance**

Freely submitted; externally peer reviewed.
Competing interests

Christopher EM Griffiths has received honoraria and/or research grants from AbbVie, Almirall, BMS, Celgene, Eli Lilly, Janssen, LEO pharma, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and UCB Pharma. Darren M Ashcroft reports research grants from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, UCB, and the LEO Foundation. The other authors have declared no competing interests.

Acknowledgements

This study was conducted using data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency (MHRA). The data are provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone, and not necessarily those of the MHRA, NHS, or the UK Department of Health and Social Care. The authors would like to acknowledge all the data providers and general practice settings that made the anonymised data available for research.

Open access

This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licenses/by/4.0/).

Discuss this article

Contribute and read comments about this article: bjgp.org/letters

Figure 3. Annual incidence rate per 1000 person–years of prescribing a) topical corticosteroids; and b) topical antifungals from 10 years before the index date. Bars are 95% confidence intervals (CPRD GOLD).

CPRD = Clinical Practice Research Datalink.

Competing interests

Christopher EM Griffiths has received honoraria and/or research grants from AbbVie, Almirall, BMS, Celgene, Eli Lilly, Janssen, LEO pharma, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and UCB Pharma. Darren M Ashcroft reports research grants from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, UCB, and the LEO Foundation. The other authors have declared no competing interests.

Comparison with existing literature

Studies on the clinical diagnosis of psoriasis have been limited. The authors’ recent international e-Delphi study undertaken by the Global Psoriasis Atlas reached consensus on a set of clinical examination-based diagnostic criteria for chronic plaque psoriasis.14 These diagnostic criteria were developed to facilitate psoriasis case recognition by non-dermatologists (such as primary healthcare professionals) in an attempt to improve psoriasis diagnosis in settings where access to specialist dermatology care was restricted. In this e-Delphi study, the different clinical presentation of psoriasis across wide ethnic backgrounds and different affected body sites (that is, different psoriasis clinical phenotypes) was also captured.

Implications for research and practice

Missing a diagnostic opportunity implies that an alternative approach could have enabled an earlier and correct diagnosis.24 For the practising clinician, data from this study raise awareness regarding a missed diagnosis or misdiagnosis of psoriasis among primary care physicians and emphasises the need to improve non-dermatologists’ diagnostic skills for psoriasis via specifically designed training courses (for example, online training tools) to encourage them to follow the consensus-agreed diagnostic criteria when suspecting a diagnosis of psoriasis.14

Physicians should consider the possibility of psoriasis in people with the following medical history and symptoms and signs of a skin condition:

- frequent GP consultations for their skin-related complaints;
- received a diagnosis of seborrheic dermatitis, other eczema (including contact dermatitis, atopic dermatitis, neurodermatitis, discoid eczema, asteatotic eczema, and hand dermatitis), tinea corporis, candida skin infections, and/or pityriasis rosea in the past;
- frequently reporting itching, dry skin, rash, and skin texture changes (scale, plaque, and crust); and
- being prescribed topical corticosteroids and/or topical antifungal medication with no or minimal improvement.

Timely diagnosis of psoriasis may promote early targeted, person-specific treatment, and screening for and treatment of comorbidities thereby improving disease course and burden, and reducing the chance of cumulative life-course impairment.15,27,28 Nevertheless, early diagnosis of psoriasis could also encourage changes to a healthier lifestyle. Lifestyle changes such as weight loss, reducing alcohol intake, and smoking cessation have been suggested as possible favourable psoriasis disease-course modifiers.29,30

The findings from the current study show that people with psoriasis have an increased number of healthcare interactions for several years before a diagnosis of psoriasis is made. These results support the need to investigate further whether a missed opportunity for diagnosis of chronic plaque psoriasis could be prevented by following expert-agreed diagnostic criteria for the condition.14

Furthermore, future work might be needed to explore the pre-diagnostic period of psoriasis, using data from secondary care settings.
REFERENCES

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA Dermatol 2020; 156(19): 1945–1960.

2. Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet 2021; 397(10281): 1301–1315.

3. Damiani G, Pacilio A, Rizzi M, et al. Patients with psoriatic arthritis have higher levels of FeND than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. Clin Rheumatol 2020; 39(10): 2981–2988.

4. Conic RR, Damiani G, Schrom KP, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med 2020; 9(1): 186.

5. Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int 2018; 2018: 3140682.

6. Fiore M, Leone S, Marano AE, et al. Liver illness and psoriatic patients. Biomed Res Int 2018; 2018: 3140963.

7. Parisi R, Iskandar IF, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369:m1590.

8. Springale D, Parisi R, Kontopantelis E, et al. Incidence, prevalence and mortality of patients with psoriasis: a UK population-based cohort study. Br J Dermatol 2017; 176(3): 650–658.

9. Damiani G, Bragazzi NL, Aksut CK, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int 2018; 2018: 3140682.

10. World Health Organization. Global report on psoriasis. 2016. http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (accessed 16 Sep 2022).

11. Boehncke W-H, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.

12. Reed C, Griffiths CE. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol 2020; 100(3): axu00032.

13. Girolomoni G, Griffiths C, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatol Treat 2015; 26(2): 103–132.

14. Haroon M, Gallagher P, FitzGerald D. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015; 74(6): 1045–1050.

15. Saunte D, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173(6): 1546–1549.

16. Abo-Tabik M, Parisi R, Willis S, et al. Development of clinical diagnostic criteria for chronic plaque psoriasis: an international e-Delphi study. Br J Dermatol 2021; 185(2): 455–456.

17. Scholfield JK, Grindlay D, Williams HC. Skin conditions in the UK: a health needs assessment. 2009. https://www.nottingham.ac.uk/research/groups/cbzd/documents/hcnskinconditionsuk2009.pdf (accessed 16 Sep 2022).

18. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 2015; 44(3): 827–836.

19. Weil A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol 2019; 48(4): 1740–1745.

20. Benchimol EI, Smeeth L, Duttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 2015; 12(10): e1001885.

21. Joint Formulary Committee. British National Formulary (BNF). 2022. https://bnf.nice.org.uk (accessed 16 Sep 2022).

22. Noble M, Wright G, Smith G, Dibben C. Measuring multiple deprivation at the small-area level. Environ Plan 2006; 38(1): 169–185.

23. Deas I, Robson B, Wong C, Bradford M. Measuring neighbourhood deprivation: a critique of the Index of Multiple Deprivation. Environ Plan 2003; 369: m1590.

24. Noble S, McLennan D, Noble M, et al. The English indices of deprivation 2019. 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/839477/02019_Research_Report.pdf (accessed 16 Sep 2022).

25. Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. Ann J Clin Dermatol 2018; 19(3): 405–423.

26. Cheraghi-Sohi S, Holland F, Singh H, et al. Incidence, origins and avoidable harm of missed opportunities in diagnosis: longitudinal patient record review in 21 English general practices. BMJ Qual Saf 2021; 30(12): 977–985.

27. Haroon M, Gallagher P, FitzGerald D. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015; 74(4): 1045–1050.

28. Saraceno R, Griffiths CE. A European perspective on the challenges of managing psoriasis. JADAD Int 2006; 54(3): 581–584.

29. Trafford AM, Parisi R, Kontopantelis E, et al. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatology 2019; 155(12): 1390–1403.

30. Parisi R, Webb RT, Carr MJ, et al. Alcohol-related mortality in patients with psoriasis: a population-based cohort study. JAMA Dermatology 2017; 153(12): 1256–1262.